Lupin is currently trading at Rs. 1468.20, up by 11.80 points or 0.81% from its previous closing of Rs. 1456.40 on the BSE.
The scrip opened at Rs. 1465.10 and has touched a high and low of Rs. 1475.00 and Rs. 1464.00 respectively. So far 41,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1765.85 on 17-Mar-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1475.00 and Rs. 1441.85 respectively. The current market cap of the company is Rs. 66,307.00 crore.
The promoters holding in the company stood at 46.71%, while Institutions and Non-Institutions held 41.46% and 11.83% respectively.
Lupin has launched Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) having received an approval from the United States Food and Drug Administration (USFDA) earlier. Minastrin 24 Fe chewable tablets had US sales of $360.5 million as per IMS MAT December 2016.
Lupin’s Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) is the AB rated generic equivalent of Allergan Pharmaceuticals International’s Minastrin 24 Fe Tablets. It is indicated for use by females of reproductive age to prevent pregnancy.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.